257 related articles for article (PubMed ID: 19147757)
1. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
Bisping G; Wenning D; Kropff M; Gustavus D; Müller-Tidow C; Stelljes M; Munzert G; Hilberg F; Roth GJ; Stefanic M; Volpert S; Mesters RM; Berdel WE; Kienast J
Clin Cancer Res; 2009 Jan; 15(2):520-31. PubMed ID: 19147757
[TBL] [Abstract][Full Text] [Related]
2. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
6. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells.
Yang M; Huang J; Pan HZ; Jin J
Int J Mol Med; 2008 Oct; 22(4):489-96. PubMed ID: 18813856
[TBL] [Abstract][Full Text] [Related]
7. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.
Podar K; Shringarpure R; Tai YT; Simoncini M; Sattler M; Ishitsuka K; Richardson PG; Hideshima T; Chauhan D; Anderson KC
Cancer Res; 2004 Oct; 64(20):7500-6. PubMed ID: 15492276
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
9. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells.
Zheng W; Guan M; Zhu L; Cai Z; Chung V; Huang H; Yen Y
Anticancer Res; 2010 Jun; 30(6):1921-30. PubMed ID: 20651335
[TBL] [Abstract][Full Text] [Related]
11. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
Podar K; Gouill SL; Zhang J; Opferman JT; Zorn E; Tai YT; Hideshima T; Amiot M; Chauhan D; Harousseau JL; Anderson KC
Oncogene; 2008 Jan; 27(6):721-31. PubMed ID: 17653083
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells.
Guan M; Zhu L; Somlo G; Hughes A; Zhou B; Yen Y
Anticancer Res; 2009 Jan; 29(1):1-9. PubMed ID: 19331127
[TBL] [Abstract][Full Text] [Related]
13. Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
Yuan J; Shah R; Kulharya A; Ustun C
Leuk Res; 2010 Jul; 34(7):954-7. PubMed ID: 20138360
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.
Jaksic W; Trudel S; Chang H; Trieu Y; Qi X; Mikhael J; Reece D; Chen C; Stewart AK
J Clin Oncol; 2005 Oct; 23(28):7069-73. PubMed ID: 16129840
[TBL] [Abstract][Full Text] [Related]
15. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
[TBL] [Abstract][Full Text] [Related]
16. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
[TBL] [Abstract][Full Text] [Related]
18. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J
Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib in combination with dexamethasone for a young multiple myeloma with t(8; 14).
Li JY; Wang LX; Shen WY; Lu SF; Chen LJ; Lu H
Leuk Res; 2009 Apr; 33(4):584-6. PubMed ID: 18829108
[No Abstract] [Full Text] [Related]
20. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
Fujita T; Doihara H; Washio K; Ino H; Murakami M; Naito M; Shimizu N
Anticancer Drugs; 2007 Jul; 18(6):677-86. PubMed ID: 17762396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]